Press Releases

 
Press Releases
  Date Title and Summary View
May 29, 2002
Monrovia, CA – May 29, 2002 – Xencor, a drug discovery company, today reported results from two protein optimization programs on key pharmaceutical proteins, recombinant human growth hormone (hGH) and granulocyte-colony stimulating factor (G-CSF). Using its proprietary Protein Design AutomationTM (PDATM) technology, Xencor computatio...
PDF
Apr 18, 2002
Monrovia, CA – April 18, 2002 – Xencor, a drug discovery company focused on chemical genomics and protein optimization, today announced that Bassil Dahiyat, Ph.D., President and CEO, will chair the "Chemical Genomics-Linking Drug Activity with Protein Function" panel at the 10th annual CALBIOsummit in San Diego, CA, April 22 from 1:4...
PDF
Mar 11, 2002
Monrovia, CA – March 11, 2002 – Xencor today announced that it has exclusively licensed a patent from the Johns Hopkins University School of Medicine (US #6,190,856 B1) entitled, “Methods of Detection Utilizing Modified Bacteriophage,“ expanding the Company’s patent estate for its proprietary chemical genomics platf...
PDF
Feb 20, 2002
(BW Healthwire)–February 20, 2002—Monrovia, CA – February 20, 2002 – Xencor today announced that it has signed licensing agreements with the California Institute of Technology and Pennsylvania State University to further expand its proprietary Protein Design Automation™ (PDA...
PDF
Jan 3, 2002
(BW Healthwire)–January 03, 2002—La Jolla, CA and Monrovia, CA.- January 3, 2002 -Torrey Mesa Research Institute (TMRI), a wholly owned subsidiary of Syngenta (NYSE: SYT), today announced the signing of a three year agreement with Xencor focusing on the discovery of novel proteins that will enable new products in the food, pharmaceut...
PDF
Oct 9, 2001
(BW Healthwire)–October 09, 2001—Xencor today announced that Stephen K. Doberstein, Ph.D. has joined as Vice President, Chemical Biology and Robert E. Pacifici, Ph.D. has joined the company as Vice President, Discovery Technologies. The addition of Dr. Doberstein and Dr. Pacifici will enable Xencor to expand its platform technology b...
PDF
Aug 6, 2001
Xencor Receives Two Patents For Ultra-Fast Optimization Technology To Create A New Generation Of Biotechnology Products (BW Healthwire)–August 06, 2001—Protein Design Automation™ technology optimizes properties of proteins Xencor today announced that it has obtained two patents from the United States Patent and Trademark Office...
PDF
Jul 19, 2001
(BW Healthwire)–June 19, 2001—Paves the Way for Improved Biopharmaceuticals and New Industrial and Agricultural Products Xencor today announced that the company has been awarded a $500,000 Small Business Innovation Research (SBIR) Phase II grant from the National Science Foundation. The grant will allow Xencor to further develop its ena...
PDF
Jul 19, 2001
(BW Healthwire)–July 19, 2001—Xencor today announced that E.William Radany, Ph.D. has joined the company as Chief Business Officer and Joyce L. Morrison has joined as Vice President, Intellectual Property. Each has over 15 years of experience in their field working with life science companies. Xencor has used the proceeds from its Novem...
PDF
Jun 14, 1999
(BW Healthwire)–June 14, 1999—Xencor Inc. announced the closing of a second round of private equity financing for $12.3 million. This financing was led by Stafford Investments LLC of Chicago, Illinois and will be used to accelerate the research, development and commercialization of Xencor’s portfolio of proprietary products design...
PDF
Page: FirstPrevious ...
18
NextLast
Xencor © Copyright 2017